1. Introduction {#sec1}
===============

Bone is a dynamic tissue that remodels constantly throughout the adult life. Bone remodeling involves degradation of old or damaged bone by osteoclasts (bone resorption) and subsequent deposition of new bone by osteoblasts (bone formation) \[[@B1]\]. Bone remodeling is physiologically required to maintain calcium homeostasis, in addition to repairing bone damage induced by mechanical stress or aging \[[@B2]\]. It is a tightly regulated process under the control of physical activities and numerous polypeptides (systemic hormones, cytokines, and locally released growth and differentiation factors) \[[@B3]\]. Perturbations in bone regulatory factors can lead to net loss or gain of bone mass. The rate of bone remodeling with enhanced bone resorption increases in a variety of skeletal disorders such as postmenopausal osteoporosis, periodontal diseases, Paget\'s disease, rheumatoid arthritis, and lytic bone metastasis \[[@B4], [@B5]\].

Mesenchymal stem cells (MSCs) (also referred to as mesenchymal or multipotent stromal cells) are non-hematopoietic precursors. They were initially isolated from bone marrow (BM) (BM-MSCs) by Friedenstein and colleagues, as stromal adherent, fibroblast-like cells that have the potential to differentiate into mesodermal derivatives (osteoblasts, adipocytes, and chondrocytes)*in vitro* and regenerate heterotopic bone tissue when implanted*in vivo* \[[@B6]\]. MSCs have also been derived almost from all postnatal \[[@B7]\], fetal \[[@B8]\], and extraembryonic tissues \[[@B9]\]. Importantly, all the extraskeletal tissues in which MSCs exist do not contribute to skeletal development, homeostasis, or repair \[[@B10]\]. However, they have already shown a potent therapeutic effect on bone regeneration and bone metabolism upon local or systemic application \[[@B11], [@B12]\].

Although MSCs can be identified by common phenotypic characteristics, no specific markers for MSCs have been defined yet \[[@B13]\]. To unify MSC characteristics across different tissue types and various culture conditions, the International Society for Cellular Therapy (ISCT) has proposed minimal criteria to define adherent cultured cells as MSCs. These criteria include (1) plastic adherence when maintained in standard culture conditions; (2) the expression of CD105, CD73, and CD90 and lack of expression of CD45, CD34, CD14 or CD11b, CD79a or CD19, and HLA-DR surface markers; and (3)*in vitro* tri-lineage differentiation to adipogenic, chondrogenic, and osteogenic cells \[[@B14]\].

Over the past few years, the therapeutic potential of MSCs has been exploited at preclinical and clinical settings \[[@B15], [@B16]\]. This may be attributed to two main functional paradigms. The first relates the effective ability of MSCs to specific engraftment at the site of injury \[[@B17], [@B18]\] and tissue replacement via multipotency \[[@B19]\]. Tracking studies showed that intravenously infused MSCs in different disease models were entrapped in the lungs, and only a transient portion appeared in the damaged organs. However, functional improvement was observed in such models with poor or absent transdifferentiation \[[@B20], [@B21]\]. These studies and others attributed the regenerative potential of MSCs to the second proposed paradigm, in which MSCs exert beneficial effects on other cells via secretion of bioactive molecules (paracrine action). MSC paracrine factors can be antiapoptotic, mitotic, supportive for tissue resident progenitors, angiogenic, immunomodulating, or chemoattractant \[[@B22], [@B23]\].

The role of MSCs within BM stroma is not limited to their function as the progenitors of various types of mesodramal cells (osteoblasts, chondrocytes, adipocytes, and marrow stromal cells). MSCs have also been demonstrated to produce regulatory factors that affect osteoclast development and bone resorption. However, the effect of MSCs on osteoclastogenesis seems to be complex and dependent on the pathophysiological environment. In this review, the controversial effects of MSCs, especially those derived from BM, on the processes of osteoclastogenesis and bone resorption are discussed.

2. Osteoclasts and Osteoclastogenesis {#sec2}
=====================================

Osteoclasts are multinucleated, bone-resorbing cells. They develop efficient machinery for dissolving crystalline hydroxyapatite and degrading organic bone matrix rich in collagen fibers \[[@B24]\]. Osteoclasts originate from myeloid precursors, which arise from the bone marrow hematopoietic stem cells (BM-HSCs). They share a common origin with different immune cells such as megakaryocytes, granulocytes, monocytes, and macrophages \[[@B24]--[@B26]\]. Osteoclasts can be also derived from mature monocytes and macrophages when a suitable microenvironment is provided \[[@B27]\] ([Figure 1](#fig1){ref-type="fig"}). In addition to the common origin, osteoclasts play a phagocytic role in the bone, similar to that of macrophages in the immune system, and accordingly are called bone-specific macrophages \[[@B28]\]. Furthermore, osteoclasts function as immunomodulators in pathologic states, and via secreting various mediators, they participate in the pathogenesis of inflammatory bone loss \[[@B29]\]. Osteoclasts can thus be considered a member of the immune cells.

Osteoclast development (osteoclastogenesis) within a bone microenvironment is a multistep process. This sequential process is mainly under the control of an extensively investigated triad-system, which includes RANKL, RANK, and OPG \[[@B5]\]. Receptor activator for nuclear factor kappa B ligand (RANKL), alternatively named TNF-related activation induced cytokine (TRANCE) \[[@B30]\], osteoclast differentiation factor (ODF) \[[@B31]\], or osteoprotegerin ligand (OPGL) \[[@B32]\], is a member of the tumor necrosis factor (TNF) superfamily of cytokines \[[@B5]\]. RANKL, synthesized by mesenchymal cells, has been identified as the principal cytokine of the osteoclastic differentiation and activation during physiological bone remodeling \[[@B31]\]. RANKL signals through RANK expressed on osteoclasts and their progenitors \[[@B33], [@B34]\], inducing diverse cascades that mediate osteoclast development and activity \[[@B35]\]. To maintain normal bone homeostasis, RANKL signaling must be properly regulated. Osteoprotegerin (OPG) \[[@B36]\], also known as osteoclast inhibitory factor (OCIF) \[[@B32]\], is a non-signaling decoy receptor expressed by osteoblasts and other bone marrow stromal cells in response to anabolic agents such as estrogen and bone morphogenetic proteins (BMPs) \[[@B37]\]. OPG is a soluble member of the tumor necrosis factor receptor (TNFR) superfamily and it acts by disrupting the interaction between RANKL and RANK, inhibiting bone resorption \[[@B36]\]. Therefore, RANKL/OPG ratio is a major determinant for bone volume and health \[[@B3]\].

For efficient osteoclast differentiation from the earliest identifiable osteoclast precursors (colony forming unit-granulocyte macrophages, CFU-GM), macrophage colony stimulating factor (M-CSF, CSF-1) is required \[[@B38]\]. M-CSF is a homodimeric glycoprotein, expressed by mesenchymal cells, including MSCs \[[@B39]\], and binds to its specific tyrosine kinase receptor (c-fms/CSF-R), which is expressed on CFU-GM \[[@B38]\]. M-CSF is essential for inducing proliferation and survival of osteoclast precursors and osteoclasts \[[@B40]\]. Importantly, M-CSF promotes the expression of RANK on CFU-GM enabling them to respond to RANKL for further differentiation along the osteoclastic lineage \[[@B38]\].*Ex vivo*, recombinant RANKL along with M-CSF sufficiently induce osteoclast differentiation from osteoclastic progenitors in the absence of any supportive cells \[[@B41]\].

3. Expression of Skeletal RANKL and Its Regulation {#sec3}
==================================================

RANKL is expressed in multiple tissues including skeletal muscles, immune organs, vascular tissues, and mammary glands, where it exerts a physiological or a pathological role depending on micro-environmental factors \[[@B5], [@B37]\]. During the process of physiological bone remodelling, RANKL, the main osteoclastic effector, is expressed in a membrane bound form on many mesenchymal cells including MSCs, osteoblasts, osteocytes, and chondrocytes \[[@B31], [@B42]--[@B46]\]. Which form predominates is a point of extensive research with controversial non-conclusive results \[[@B47]--[@B49]\]. During normal bone modeling/remodeling, expression of basal RANKL is activated in response to osteotropic factors such as 1*α*,25(OH)~2~D~3~, parathyroid hormone (PTH), prostaglandin E2 (PGE2), IL-1, leukemia inhibitory factor (LIF), and oncostatin M \[[@B32], [@B50]\]. To maintain normal bone remodeling, negative regulation for RANKL expression and/or signaling is required. In addition to OPG, the main negative regulator for RANKL signaling, myriad molecules such as estrogen, and immune related mediators including IL-4 \[[@B51]\], IL-13 \[[@B51]\], IL-10 \[[@B52]\], IL-18 \[[@B53]\], IFN-*γ* \[[@B54]\], and IFN-*β* \[[@B55]\] act as osteoprotective factors against excessive bone destruction. They act via different mechanisms like interfering with increased RANKL expression or signaling, upregulating OPG expression, or inducing osteoclast apoptosis \[[@B56]\].

Interestingly, some of the cytokines and growth factors, such as IL-7, IL-12, IL-23, IL-6, and transforming growth factor beta (TGF-*β*), have shown dual osteoclastogenic and anti-osteoclastogenic properties depending on pathophysiological state of bone*in vivo* \[[@B57]\].*In vitro*, this dual effect was shown to depend on the density and differentiation stage of the osteoclast population \[[@B58], [@B59]\]. During pathologic bone remodeling associated with infection, inflammation, or malignancy, infiltrating cells within a skeleton, such as activated T \[[@B34], [@B60]\] and B lymphocytes \[[@B61]\], inflamed synovial fibroblasts \[[@B62]\], osteoclasts \[[@B63]\], endothelial cells \[[@B64]\], and cancer cells \[[@B65], [@B66]\], play a role in enhanced RANKL expression via direct or paracrine mechanisms. These cells can directly express RANKL \[[@B61], [@B62], [@B65]\], which may be in a soluble form \[[@B67]\]. Moreover, these cells can enhance the expression of abnormal high levels of RANKL by mesenchymal cells via production of pro-osteoclastogenic factors and cytokines such as TNF, IL-17, IL-1, or epidermal growth factor (EGF) \[[@B68], [@B69]\].

4. Immunoregulatory Effects of MSCs {#sec4}
===================================

In addition to their stem/progenitor properties, MSCs display immunomodulatory functions and immunosuppressive actions both*in vitro* and*in vivo* \[[@B70]\]. The unique immunosuppressive feature of MSCs is especially beneficial in the treatment of autoimmune diseases, such as Crohn\'s disease \[[@B71]\], graft versus host disease (GVHD) \[[@B72], [@B73]\], and diabetes \[[@B74]\].

The immunosuppressive effects of MSCs are mediated either through MSCs-immune cells direct contact or by secretion of soluble factors \[[@B23], [@B75]--[@B77]\]. These factors include indoleamine 2,3-dioxygenase (IDO) or nitric oxide (NO) \[[@B78]\], IL-6 \[[@B79]\], IL-10 \[[@B80]\], and PGE2 \[[@B81]\], in addition to hemeoxygenase-1 \[[@B82]\], M-CSF \[[@B83]\], TGF-*β*1 \[[@B84]\], vascular endothelial growth factor (VEGF) \[[@B85]\], antagonistic variant of the chemokine CCL2 \[[@B86]\], TNF-stimulated gene-6 (TSG6) \[[@B87]\], interleukin 1 receptor antagonist (IL-1Ra) \[[@B88]\], soluble human leukocyte antigen-G5 (sHLA-G5) \[[@B89]\], and hepatocyte growth factor (HGF) \[[@B90], [@B91]\].

For the immunosuppressive action of MSCs to take place, a preliminary activation is elicited by proinflammatory cytokines released from the inflammatory microenvironment \[[@B70], [@B86], [@B92]\]. MSC activation can be induced either by IFN*γ* alone \[[@B93]\] or concomitant with TNF, IL-1*α*, or IL-1*β* \[[@B94]--[@B96]\]. In addition, the prominent inflammatory cytokine, IL-17, boosts immunosuppression by MSCs both*in vitro* and*in vivo* \[[@B97]\]. Importantly, MSCs show a dual regulatory role on immune cells where their action can be switched between immune stimulation and immune suppression according to the inflammatory milieu, and the levels and types of the inflammatory cytokines \[[@B70], [@B76], [@B98]\]. When the inflammation is mild, the effect of MSCs on immune cells is switched from immunosuppression to immune enhancing, drastically promoting the function of immune cells \[[@B76], [@B96], [@B98]--[@B101]\]. Insufficient inflammatory stimulus causes MSCs to enhance the immune response through the production of chemokines that recruit immune cells to sites of inflammation/injury. However, this low stimulus is not sufficient to allow the MSCs to exert their immune suppressive action on the immune cells, leading to accumulation of the latter and enhanced inflammation \[[@B96], [@B99]\]. This immune plasticity achieves a balance between proinflammatory and anti-inflammatory processes in order to maintain tissue integrity and homeostasis \[[@B98], [@B102]\].

Interestingly, administration of immunosuppressants was shown to disable the immunosuppressive action of MSCs, altering the therapeutic application of MSCs in immune-mediated disorders \[[@B98], [@B103]\].

Evidently, to achieve the anti-inflammatory therapeutic effect of MSCs for the treatment of inflammatory/autoimmune disorders, several factors should be considered. These factors include the dynamics of inflammation, the strength of immune system activation, the types of inflammatory cytokines, and the effects of immunosuppressant \[[@B98]\].

Under sufficient inflammatory conditions, MSCs exert their immune suppressive effects on the different types of immune cells through proliferation inhibition and functional modulation \[[@B77]\]. In addition, MSCs are able to suppress the differentiation of the immune cells from their precursors at the very early stages of the immune response. For example, human MSCs could exhibit an inhibitory effect on the differentiation of CD34^+^ progenitors and on monocyte differentiation into dendritic cells \[[@B83], [@B104], [@B105]\]. MSCs were shown to suppress the terminal differentiation of B cells into antibody secreting cells or plasma cells \[[@B106], [@B107]\]. Furthermore, MSCs were shown to suppress the differentiation of cytotoxic T lymphocytes from their precursors \[[@B108]\] and prevent the differentiation of naive CD4^+^ T cells into T helper 17 cells \[[@B109]\]. As osteoclasts are considered osteoimmune cells, under normal conditions or when the inflammatory status is not sufficient to elicit the immunosuppressive action, MSCs may normally support and enhance osteoclastogenesis. However, under sufficient inflammatory conditions, MSCs may suppress osteoclast formation. This hypothesis was supported by a number of*in vitro* human and murine studies in which osteoclast precursors were co-cultured with MSCs, and the effect of MSCs on*ex vivo* osteoclast formation and activity was assessed.

5. Studies Investigating the Effect of MSCs on Osteoclastogenesis*Ex Vivo* {#sec5}
==========================================================================

Early studies identified that several preadipocytic, pre-osteoblastic stromal \[[@B110], [@B111]\], or mature osteoblasts \[[@B112]\] can support osteoclast formation when co-cultured with osteoclast precursors. Treatment of stromal cells/osteoblasts with a bone resorption stimulator like 1*α*,25(OH)~2~D~3~ or PTH and direct contact with osteoclast progenitors were essential for osteoclastogenesis. After discovery of RANKL, several*in vitro* and*in vivo* studies attempted to establish a link between the differentiation state of cells of osteoblastic lineage and their osteoclastogenesis supporting potential. However, the data were contradictory. Some of these studies showed that undifferentiated/immature osteoblastic/stromal cells exhibited not only stronger osteoclastogenesis supportive potential \[[@B39], [@B47], [@B113]--[@B115]\], but also higher RANKL expression \[[@B115]\]. In contrast, others concluded that commitment of osteoprogenitors into mature osteoblasts enhances their osteoclastogenesis supportive properties \[[@B116]--[@B119]\].

In one of the first studies to investigate the effect of MSCs on osteoclastogenesis \[[@B39]\], hBM-MSCs were co-cultured with the osteoclast progenitors, CD34^+^ hHSCs. MSCs supported the growth and differentiation of HSCs into functional osteoclasts in the absence of added hormones, cytokines, and growth factors. In this study, MSCs stimulated osteoclastogenesis in both cell contact and trans-well assays, indicating that both osteoclastogenic surface proteins and soluble factors mediated MSC action. However, in the trans-well assays, osteoclast formation was reduced by 75%. Therefore, it was concluded that cell-cell contact has a much greater potency in stimulating osteoclastogenesis than soluble mediators. By analyzing the effect of adding the osteotropic factor, 1*α*,25(OH)~2~D~3~, to the co-culture system, the authors reported that osteoclast formation was significantly enhanced in the presence of 10^−9^ M 1*α*,25(OH)~2~D~3~. However, the higher concentration (10^−8^ M) could not similarly enhance osteoclast formation \[[@B39]\]. Consistently, Baldock et al. \[[@B120]\] reported that maximal osteoclastogenic effect of 1*α*,25(OH)~2~D~3~ in co-cultures of osteoblasts and monocytes was at concentration of 10^−9^ M, while this effect was reduced at higher concentrations. Mbalaviele et al. \[[@B39]\] attributed the osteoclastogenic effect of MSCs to their expression of the well-known osteoclastogenic cytokines, IL-6, IL-11, M-CSF, stem cell factor, and LIF.

Recently, Ma et al. \[[@B121]\] demonstrated that the osteoclastogenesis-supportive role of MSCs is correlated with the inflammatory status of bone marrow from which they are derived. Bone marrow cells (osteoclast progenitors) from wild type mice were co-cultured with BM-MSCs derived from both wild type and systemic lupus erythematosus (SLE) model (MRL/lpr mice), in the presence of vitamin D3 and Prostaglandin E2. BM-MSCs isolated from MRL/lpr mice, characterized by chronic systemic inflammation and local bone marrow inflammation, showed enhanced osteoclastogenic activity compared to that of wild type MSCs.

The stimulatory action of MSCs on osteoclastogenesis represents only one aspect of their regulatory effect on osteoclast differentiation, whereas MSCs can also exert an inhibitory effect on this process. This dual effect of MSCs on differentiation and function of osteoclasts was clearly shown by Zhu et al. \[[@B122]\]. In this study, the authors firstly investigated the effect of non-treated MSCs on osteoclast development by co-culturing murine BM-MSCs with the murine osteoclast precursors, CD11b^+^ monocytes, in the absence or presence of relatively low doses of recombinant mouse M-CSF and RANKL. MSCs independently supported osteoclast development, and this effect was enhanced by M-CSF and RANKL. The stimulatory effect of non-treated MSCs on osteoclast formation was attributed to their ability to express the osteoclastogenic factors RANKL, M-CSF, and IL-6. It was supposed that addition of TNF, formerly known as TNF*α*, might strengthen the positive effect of MSCs on osteoclast formation, since TNF is one of the important proinflammatory cytokines that was shown to promote osteoclastogenesis \[[@B123]--[@B125]\]. However, the study reported that MSC treatment with TNF prior to culture with monocytes, or addition of TNF to the MSCs/monocytes co-culture system resulted in a strong inhibition of osteoclast formation and activity. TNF upregulated OPG expression by MSCs in a time- and dose-dependent manner, while it slightly downregulated M-CSF, RANKL, and IL-6 expression. Furthermore, when TNF-stimulated MSCs and monocytes were separated by a 0.4 *µ*m pore size membrane, the number of osteoclasts was increased indicating that not only soluble factors, but also surface proteins contributed to the inhibitory effect. Hence, TNF could switch the effect of MSCs on osteoclastogenesis from being supportive to being suppressive. This action of TNF may be considered a part of its role as a proinflammatory mediator enhancing the MSC immunosuppressive effects. MSC inhibition of inflammation associated osteolysis may be one of their unique immunosuppressive characteristics. Importantly, treatment of MSCs with rheumatoid arthritis synovial fluid (RASF), in which the concentrations of TNF were detected, modulated osteoclast generation in a close relation with the TNF level in RASF. MSCs promoted osteoclast formation when TNF concentration was relatively low, while they inhibited osteoclast generation after treatment with high TNF concentrations. These studies provided further evidence for the ability of MSCs to switch between the pro- and anti-inflammatory phenotypes \[[@B98]\]. It is noteworthy that the immunosuppressive effect of the MSCs was not always correlated with the dose of TNF in RASF in some patients. Therefore, it is possible that other factors in RASF may regulate MSC effect on osteoclastogenesis \[[@B122]\].

When studying the effect of MSCs on osteoclastogenesis, Oshita et al. \[[@B126]\] co-cultured MSCs with peripheral blood mononuclear cells (PBMCs), stimulated with relatively high levels of RANKL and M-CSF using a trans-well system. Under these conditions, MSCs exerted a suppressive effect on osteoclast differentiation and activity and this effect was partially attributed to OPG expression. It is suggested that these high levels of RANKL and M-CSF may have a similar effect as TNF stimulating the MSC anti-osteoclastogenic action. Unexpectedly, even in the absence of RANKL and M-CSF, MSCs constitutively produced OPG in levels sufficient to inhibit osteoclastogenesis. However, this latter finding was contradictory with that reported by Mbalaviele et al. \[[@B39]\] and Zhu et al. \[[@B122]\] and needs to be further tested.

Oshita et al. \[[@B126]\] proposed that not only OPG, but also other soluble mediators might be involved in inhibition of osteoclastogenesis by MSCs. The effect of MSCs on osteoclastogenesis and the involved mediators were also investigated by Takano et al. \[[@B127]\]. They reported that osteoclast formation was significantly inhibited in the presence of MSCs through secretion of the inhibitory factors OPG and IL-10. It is noteworthy that Oshita et al. \[[@B126]\] were unable to detect IL-10 in their culture system. IL-10 is an immunosuppressive and anti-inflammatory cytokine, which plays a critical role in limiting tissue injury during infections. It also has a role in protection against autoimmunity by limiting the duration and intensity of immune and inflammatory reactions. IL-10 is one of the immune regulatory cytokines secreted by MSCs as a part of their immunosuppressive reaction \[[@B128]\].*In vitro* and*in vivo* studies have shown an important role for IL-10 in suppressing osteoclastogenesis \[[@B52], [@B129]\]. IL-10 inhibits early stages of osteoclast differentiation through disrupting RANKL induced signaling \[[@B52]\] or co-stimulatory signals \[[@B130]\].

Takano et al. \[[@B127]\] also reported the secretion of TGF-*β*1 by MSCs in their co-culture system. The role of TGF-*β*1 in osteoclastogenesis and bone resorption is very complex and biphasic \[[@B131]\]. In culture, it depends on many factors including TGF-*β*1 concentration \[[@B57], [@B131]\]. TGF-*β*1 seems to stimulate osteoclast development \[[@B132]\], survival \[[@B133]\], and recruitment \[[@B134]\], mostly at low doses \[[@B131]\]. On the other hand, it inhibits osteoclastogenesis \[[@B132], [@B135]\] and promotes osteoclast apoptosis \[[@B136]\], particularly at high concentrations \[[@B131]\]. However, it is suggested that TGF-*β*1 effect on bone resorption*in vivo* depends on the local microenvironment such as the presence of other pro- or anti-osteoclastic cytokines \[[@B57]\].

Importantly, Takano et al. \[[@B127]\] did not add the commonly used RANKL and M-CSF to the culture medium; instead, their culture medium contained heat treated conditioned medium derived from the rat osteoblastic cell line ROS 17/2.8 (htROSCM). htROSCM strongly stimulated osteoclast differentiation in the presence of 1*α*,25(OH)~2~D~3~ in rat bone marrow culture systems \[[@B137]--[@B140]\]. However, when MSCs were added in the htROSCM-containing culture system, the outcome was reversed where osteoclast formation was inhibited \[[@B127]\]. Interestingly, the non-heat-treated ROSCM strongly inhibited osteoclast formation. Therefore, the stimulatory activity of htROSCM is apparently derived from heat stable protein(s), which are different from the heat labile colony stimulating factors (CSFs), including M-CSF and granulocyte macrophage CSF (GM-CSF). It is possible that the stimulatory effect of htROSCM is due to the denaturation of the inhibitory factor(s). Furthermore, heat treatment may activate some stimulating factor(s) \[[@B137]\]. Further characterization of htROSCM and the factor(s) responsible for their activity is still required. Takano et al. \[[@B127]\] showed that MSCs in the presence of htROSCM, a potent stimulator for osteoclastogenesis, exerted an inhibitory effect on osteoclast differentiation. In this study, the efficiency of MSCs to inhibit osteoclastogenesis was higher (by 10-fold) in the direct cell-cell contact co-culture system in comparison with the contact-free trans-well system, indicating that some putative potent anti-osteoclastogenic molecules are expressed on the MSCs. Another study by Varin et al. \[[@B141]\] investigated the effect of MSCs on osteoclast formation through the direct interaction of the MSC surface marker CD200 with its receptor (CD200R), expressed on the osteoclast precursors.

CD200 is a newly identified marker for MSCs and could be efficiently used to purify native MSCs \[[@B142]\]. CD200 is an immunoglobulin superfamily member expressed on various types of cells and acts as immunosuppressive cell surface glycoprotein \[[@B143]\]. CD200 receptor is a type 1 transmembrane glycoprotein, mainly expressed on cells of myeloid lineage such as monocytes and macrophages \[[@B141], [@B143]\]. The CD200-CD200R interaction could initiate an immunosuppressive signal that leads to different immunomodulatory actions and anti-inflammatory effects downregulating several immune cell functions, especially macrophages \[[@B143], [@B144]\].

Varin et al. \[[@B141]\] demonstrated that CD200-CD200R interaction can block osteoclast formation and their bone degradation capacity by inhibiting the downstream RANK signaling pathway. CD200^+^, and not CD200^−^, MSC population significantly suppressed osteoclast formation. However, both populations expressed similar levels of OPG indicating that the inhibitory effect of CD200^+^ fraction is independent of OPG secretion. It is noteworthy that the total population of MSCs could exert an inhibitory effect on osteoclast differentiation. Importantly, the co-culture system in this study contained relatively high concentrations of the osteoclastogenic factors M-CSF and RANKL. The dual modulatory role of MSCs on osteoclastogenesis is shown in [Figure 2](#fig2){ref-type="fig"}.

It is noteworthy that the expression of CD200 on MSCs is origin dependent. Bone marrow is the most traditional source of CD200^+^ MSCs; however, its expression pattern was found to be varying from high to medium and low according to the donor. Meanwhile, umbilical cord blood derived MSCs (UCB-MSCs) were constantly negative for CD200 \[[@B143]\]. In addition, it was found that fetal, but not placental, MSCs preferentially express CD200 \[[@B145]\]. Similarly, CD200 was found to be a potential marker for visceral adipose stem cells (VS-ASC) but not subcutaneous adipose stem cells (SC-ASC) \[[@B146], [@B147]\]. Interestingly, MSCs isolated from Wharton\'s jelly expressed CD200 at higher proportions compared to bone marrow and adipose tissue MSCs, suggesting that the former could offer more immunomodulatory capacities \[[@B144]\].

The effect of the inflammatory signals on the MSC expression of CD200 was investigated, where neither Wharton\'s jelly nor adipose tissue MSCs showed a modulation of their CD200 expression upon inflammatory stimulation. In contrast, BM-MSCs showed an increase in the expression of CD200 when treated with proinflammatory cytokines. INF-*α*, TNF, and IL-1 induced a slight increase, while IFN*γ* induced a significant upregulation of CD200 expression on BM-MSCs \[[@B144]\]. Purified from an appropriate source, CD200^+^ MSC population may represent a potent transplantable therapeutic modality for application in several inflammatory and autoimmune diseases.

6. The*In Vivo* Anti-Osteoclastogenic Effect of MSCs {#sec6}
====================================================

The therapeutic approach of MSC transplantation to recover bone loss in different models of inflammatory diseases associated with abnormal bone metabolism, such as primary or secondary osteoporosis and rheumatoid arthritis (RA), has been reported. MSC transplantation improved bone matrix formation and reduced bone resorption leading to improved bone density and structure in steroid induced osteoporosis model \[[@B148]\], rat model of adjuvant arthritis (AA) \[[@B127]\], and MRL/lpr mice (model of SLE with secondary osteoporosis) \[[@B121]\]. However, little was known about the therapeutic targets of MSC transplants in these models. Ma et al. \[[@B121]\] showed that BM-MSCs of MRL/lpr mice were the therapeutic targets of transplanted human MSCs derived from healthy donors. In both SLE patients and MRL/lpr mice, increased levels of the proinflammatory cytokine IL-17 in their bone marrow impaired the osteogenic potential and accelerated the osteoclastic inductive effect of BM-MSCs. hMSC transplantation led to downregulation for the abnormal expression of IL-17 and recovery of the impaired functions of recipient BM-MSCs, resetting the bone homoeostasis.

Importantly, in accordance with the*in vitro* results, there was no effect for MSC transplantation in wild type mice on bone metabolism, suggesting that recipient\'s inflammatory milieu might influence the transplanted MSCs\' ability to correct the imbalanced bone metabolism \[[@B121]\].

7. Conclusion {#sec7}
=============

Based on the aforementioned*in vitro* studies, it can be concluded that MSCs have a dual effect on osteoclasts, similar to their effect on other immune cells. This effect is dependent on the microenvironment. The osteoclastic modulatory effect of MSCs seems to be correlated with the intensity of the osteoclast induction conditions. In the studies that support the osteoclastogenic stimulatory role of MSCs, osteoclast inducing factor(s) such as M-CSF and RANKL were either absent \[[@B39], [@B121]\] or present at low concentrations \[[@B122]\]. However, in studies addressing the inhibitory effect of MSCs on osteoclastogenesis, a strong osteoclast inducing factor was found. In two of these studies, a relatively high concentration of the commonly used osteoclastogenic cytokines, RANKL and M-CSF, was added to the culture media, leading to stimulation of MSC anti-osteoclastogenic effect \[[@B126], [@B141]\]. However, treatment of MSCs with the proinflammatory cytokine TNF prior to co-culture with monocytes or addition of TNF to the MSCs/monocytes co-culture system switched the effect of MSCs on osteoclastogenesis from being supportive to being suppressive \[[@B122]\]. Moreover, when a potent osteoclast-inducing medium (htROSCM) was used, MSCs significantly suppressed osteoclastogenesis in this system \[[@B127]\] ([Table 1](#tab1){ref-type="table"}). Hence, it can be postulated that the presence of intense osteoclast inducing factors in co-culture systems may create a state similar to the inflammatory pathological conditions*in vivo*, which stimulates MSCs to exhibit their osteoclastogenic suppressive effect. However, this speculation needs further investigation, which may be beneficial in guiding the future therapeutic use of MSCs in inflammatory bone loss disorders.

8. Future Perspectives {#sec8}
======================

(i)The regulatory effect of MSCs on osteoclasts seems to be dual and dependent on the inflammatory/immune status of the microenvironment in which they are applied. As previously shown, exposing MSCs to TNF switched their action on osteoclasts from being supportive to being suppressive; therefore, the effect of different types and levels of other proinflammatory and/or pro-osteoclastogenic factors such as IL-1*α*, IL-1*β*, and IFN*γ* on the osteoclastogenic modulatory role of MSCs needs to be also evaluated. It is noteworthy that several cytokines including TGF-*β*1, IL-4, and IL-1*β* were found to upregulate OPG expression in marrow stromal cells ST2, osteoblastic cells MC3T3-E1 \[[@B149]\], and endothelial cells \[[@B150]\], and they may also be involved in upregulating the expression of OPG in MSCs.(ii)Since MSC therapeutic efficacy in treatment of inflammatory conditions can be enhanced by precon-ditioning of MSCs with proinflammatory cytokines, growth factors, or small molecules \[[@B151]\], similarly, MSC pretreatment with these factors may also be recommended to promote their anti-osteoclastogenic action. On the other hand, systemic or local profiling of pro-osteoclastogenic cytokines in patients with inflammatory bone loss disorders before MSC administration may be beneficial in determining the appropriate disease stage/timing at which MSCs should be applied to exert the required anti-osteoclastogenic therapeutic effect.(iii)In addition to CD200, surface proteins which participate in the modulatory role of MSCs on osteoclastogenesis need further investigation. This would specify MSC subpopulations with anti-osteoclastogenic potential that would have a promising clinical use in inflammatory/autoimmune bone loss diseases.(iv)With advancing age, BM-MSCs showed decrease in proliferation rate, differentiation capacity, number of osteoprogenitor cells, and bone migration capacity \[[@B152], [@B153]\]. Whether aging would also affect the role of MSCs on osteoclast formation and activity requires to be investigated, taking into account that aging is characterized by increased inflammatory milieu \[[@B154]\].
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###### 

Studies addressing the effects of MSCs on osteoclastogenic culture systems.

  Reference     Source of cells   Osteoclast precursors   Supplemented factors which support osteoclastogenesis   Osteoclastogenesis related factors secreted by MSCs                                                                         
  ------------- ----------------- ----------------------- ------------------------------------------------------- ----------------------------------------------------- ---------------------------- ---------------------------------------- -----------------------------------------------
  \[[@B39]\]    Human             CD34^+^ HSCs            ---                                                     ---                                                   None or 10^−9^ or 10^−8^ M                                            IL-6, IL-11, M-CSF, stem cell factor, and LIF
  \[[@B121]\]   Mice              Bone marrow cells       ---                                                     ---                                                   +ve                          Prostaglandin E2                         ---
  \[[@B122]\]   Mice              CD11b^+^ monocytes      None or 10 or 20 ng/mL                                  10 or 20 ng/mL                                        ---                          TNF may be present                       RANKL, M-CSF, IL-6, and OPG
  \[[@B126]\]   Human             PBMCs                   50 ng/mL                                                50 ng/mL                                              None or 10^−7^ M                                                      OPG
  \[[@B141]\]   Human             PBMCs                   50 ng/mL                                                50 ng/mL                                              ---                                                                   ---
  \[[@B127]\]   Rats              Bone marrow cells       ---                                                     ---                                                   10^−8^ M                     htROSCM was added to the culture media   TGF-*β*1, OPG, and IL-10
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